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Abstract 
Aim: To develop a simple risk-score model for predicting in-hospital cardiac arrest (CA) 
among patients hospitalized with suspected non-ST elevation acute coronary syndrome 
(NSTE-ACS). Methods: Using the Swedish Web-system for Enhancement and Development 
 2 
of Evidence-based care in Heart disease Evaluated According to Recommended Therapies 
(SWEDEHEART), we identified patients (n=242 303) admitted with suspected NSTE-ACS 
between 2008 and 2014. Logistic regression was used to assess the association between 26 
candidate variables and in-hospital CA. A risk-score model was developed and validated 
using a temporal cohort (n=126 073) comprising patients from SWEDEHEART between 
2005 and 2007 and an external cohort (n=276 109) comprising patients from the Myocardial 
Ischaemia National Audit Project (MINAP) between 2008 and 2013. Results: The incidence 
of in-hospital CA for NSTE-ACS and non-ACS was lower in the SWEDEHEART-derivation 
cohort than in MINAP (1.3% and 0.5% vs. 2.3% and 2.3%). A seven point, five variable risk 
VFRUHDJH\HDUVSRLQW67-T abnormalities (2 points), Killip Class >1 (1 point), heart 
UDWH  RU 0 bpm (1 point), and systolic blood pressure <100 mmHg (2 points) was 
developed. Model discrimination was good in the derivation cohort (c-statistic 0.72) and 
temporal validation cohort (c-statistic 0.74), and calibration was reasonable with a tendency 
towards overestimation of risk with a higher sum of score points. External validation showed 
moderate discrimination (c-statistic 0.65) and calibration showed a general underestimation of 
predicted risk. Conclusions: A simple points score containing five variables readily available 
on admission predicts in-hospital CA for patients with suspected NSTE-ACS. 
 
Key Words: In-Hospital Cardiac Arrest; Acute Coronary Syndrome; Non-ST Elevation 
Acute Coronary Syndrome; Risk Score; Risk Stratification 
 
Introduction 
In-hospital cardiac arrest (CA) is an infrequent, but life-threatening complication of a non-ST 
elevation acute coronary syndrome (NSTE-ACS). The cause of in-hospital CA is usually 
ventricular tachycardia (VT) or ventricular fibrillation (VF), reported to occur in 1.5-2.1% of 
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patients1, 2. Although less common, patients are also at risk of non-VT/VF CA3. There are no 
contemporary clinical risk scores available to estimate the risk of hospital CA using data 
obtained at the time of admission among patients with suspected NSTE-ACS.  
 
Recommendations for continuous ECG-monitoring of patients admitted to hospital with 
suspected NSTE-ACS differ, but guidelines emphasize the importance of early risk 
stratification to reduce adverse clinical outcomes4, 5. The current American Heart Association 
/ American College of Cardiology guidelines for the management of patients with NSTE-ACS 
suggest several clinical factors predictive of VT/VF including signs of heart failure at 
presentation, hypotension, tachycardia, cardiogenic shock and poor TIMI flow4. The latest 
European guidelines on the management of NSTE-ACS recommend ECG-monitoring until 
non-ST elevation myocardial infarction is ruled out or when the diagnosis is established, in 
low-ULVN SDWLHQWV XQWLO UHYDVFXODUL]DWLRQ RU  KRXUV RU SURORQJHG PRQLWRULQJ RQO\ LI
intermediate/high-risk features are present (e.g. hemodynamic instability, major arrhythmias, 
left ventricular ejection fraction <40%, failed reperfusion and the presence of critical stenosis 
or complications related to percutaneous coronary intervention (PCI)5. 
 
The aim of this study was to develop an easy-to-use clinical risk-score that may help the 
physician assess the risk of in-hospital CA and hence the need for cardiac rhythm monitoring 
and level of surveillance in patients admitted with suspected NSTE-ACS. For this purpose, 
we identified predictors of CA present at hospital admission and developed and validated a 
risk-score model for in-hospital CA in the Swedish Web-system for Enhancement and 
Development of Evidence-based care in Heart disease Evaluated According to Recommended 
Therapies (SWEDEHEART). We externally validated the risk score in the United Kingdom 
Myocardial Ischaemia National Audit Project (MINAP). 
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Methods 
Study population  
The study comprised all patients admitted to a coronary care unit (CCU) with suspected or 
confirmed ACS and registered in SWEDEHEART. Data on clinical variables at admission, 
current medication, treatment and procedures during hospitalization, and final diagnoses are 
recorded as part of the registry. SWEDEHEART has been described in detail previously6. All 
patients are informed about collection of data in the registry and are allowed to opt-out. 
SWEDEHEART is cross-linked with the Swedish National Patient Registry, to enrich data on 
previous medical history, and with the Swedish Population registry to obtain date of death. 
The protocol of this study was approved by the regional ethics committee in Stockholm, 
Sweden and was conducted complying with the Declaration of Helsinki. 
 
Derivation cohort 
All patients at least 18 years old registered in SWEDEHEART between January 1 2008 and 
December 31 2014 were eligible (n=353 140). Patients could be eligible for entry more than 
once. Exclusion criteria included ST-elevation myocardial infarction (n=40 798), CA prior to 
admission (n=4200), and missing data regarding CA prior to admission (n=54 864) or in-
hospital CA (n=13 281). In total, 242 303 cases (187 662 unique patients) remained in the 
study population for analyses (figure 1).  
 
Definition of CA  
In-hospital CA requiring defibrillation or cardiopulmonary resuscitation is recorded 
prospectively as part of SWEDEHEART. TKLV YDULDEOH LV FDWHJRUL]HG DV ³VT/VF´ ³other 
causes of CA´RU³QRCA´. Given that there may be overlap between the first two categories 
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all analyses were conducted using a dichotomized variable defined as in-hospital CA ³\HV´RU
³QR´  
 
Statistical analyses 
Baseline characteristics for continuous data are presented as median (interquartile range) or as 
numbers and proportions for categorical data. 
 
Risk score derivation 
Logistic regression was used to assess the association between in-hospital CA and baseline 
patient characteristics. Candidate variables were incorporated based on findings from prior 
studies, current NSTE-ACS guideline recommendations, clinical relevance, and availability at 
admission 1, 2, 4, 5, 7. Continuous variables were divided into deciles and the most appropriate 
cut-offs were chosen, without testing for non-linear relationships or interactions. Backward 
selection was performed using a 0.05 significance level. In the final model, all included 
variables were dichotomized. 
 
The following 26 variables were tested in the logistic regression models: age, gender, weight, 
smoking status (dichotomized as current smoker yes/no); prior diseases including 
hypertension, diabetes, chronic obstructive pulmonary disease, heart failure, myocardial 
infarction, stroke, and peripheral vascular disease; prior coronary interventions including PCI 
and coronary artery bypass graft (CABG) surgery; current pharmacological treatment 
including beta blockers, calcium antagonists, digoxin, aspirin, angiotensin-converting enzyme 
(ACE) inhibitors / angiotensin receptor blockers (ARB), and statins; clinical findings at 
presentation including Killip class, heart rate, systolic blood pressure, and 
electrocardiographic ST-T-changes; laboratory findings at presentation including glucose, 
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hemoglobin, and estimated glomerular filtration rate (eGFR) based on the CKD-EPI (Chronic 
Kidney Disease Epidemiology Collaboration) formula8. Given that only peak values are 
reported in SWEDEHEART and therefore on admission assay results were not available in 
the dataset , the cardiac troponin concentration was not included.  
 
A risk-score model was developed using the points system described by Sullivan et al9. 
Briefly, as dichotomous variables were included in the model, each risk factor could take on 
the values 0 or ßi, where ßi represented the respective estimate of the regression coefficient of 
the multiple logistic-regression model. The regression coefficient of one of the variables was 
defined as the constant, B, which corresponded to one point in the point score. Each risk 
factor was assigned points by dividing ßi by B, rounded to the nearest integer. The estimated 
risk was determined by adding the intercept of the estimate, ß0, to the point total multiplied by 
the constant B and then transforming the sum using the logistic function. Model 
discrimination was assessed using the c-statistic and calibration by comparing observed to 
predicted risk in calibration plots. 
 
Missing data 
Complete data on all candidate variables (26) was available in 159 693 (65.9%) cases. The 
most frequently missed variable, glucose, had 19.6% missing. Data was assumed to be 
missing at random. To account for missing data, multiple imputation by chained equations 
(MICE) was performed generating 20 imputed data sets. All candidate variables and the 
outcome variable were used as predictors for missing variables. For the two variables glucose 
and eGFR, two additional, auxiliary variables, insulin and oral diabetes medication were also 
used. For the final risk score model, complete data on all included variables was available in 
227 912 (94.1%) cases. The main results were compared for the imputed and complete case 
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cohorts. Patients excluded solely due to missing data regarding in-hospital CA, pre-hospital 
CA, or CA at admission were compared to patients included in the cohort in respect of 
baseline characteristics, in-hospital mortality and mortality at 30 days.  
 
Internal validation 
Since the number of events (n= 2077) was large relative to the number of predictors included 
in the final model, the risk of overfitting was considered to be negligible and bootstrapping of 
the sample not performed. This was further supported by using the heuristic shrinkage 
estimator of van Houewelingen and le Cessie with a computed estimated shrinkage factor of 
0.99710.  
 
Temporal validation 
A temporal validation was performed using data from SWEDEHEART between January 1 
2005 and December 31 2007. This cohort (n=126 073, 102 762 unique patients) was selected 
using the same inclusion and exclusion criteria as for the derivation cohort. To adjust for 
missing data multiple imputation (20 imputed data sets) was performed in the same manner as 
for the original cohort.  
 
External validation 
External validation was undertaken using anonymised data from the Myocardial Ischaemia 
National Audit Project (MINAP) between January 1 2008 and December 31 2013. MINAP 
has been described in depth elsewhere11. In-hospital CA requiring defibrillation or 
cardiopulmonary resuscitation is recorded prospectively as part of MINAP. All analyses were 
conducted using a dichotomized variable defined as in-hospital CA ³\HV´RU³QR´The same 
inclusion and exclusion criteria as for the derivation cohort were used (supplementary figure 
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1). The cohort comprised 276 109 cases. Missing data for Killip class, one of the variables in 
the final risk score model, was 72.0%. For the remaining variables included in the final risk 
score model, data missingness ranged from 0.1% to 8.7%. Multiple imputation was performed 
(10 imputed datasets) according to methods previously described for MINAP12. To adjust for 
differences in underlying risk between the development and external cohorts, a model with ß0 
calculated from MINAP was included. The National Institute for Cardiovascular Outcomes 
Research (NICOR) which includes the MINAP database (Ref: NIGB: ECC 1-06 
(d)/2011) had support under section 251 of the National Health Service (NHS) Act 2006 to 
use patient information for medical research without consent.  
 
Statistical analyses were performed with Stata version 13 (StataCorp, College station, Texas, 
USA) and R version 3.1.0 (R Foundation for Statistical Computing, Vienna, Austria).
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Results 
Derivation cohort   
In total, 2077 (0.9%) cases of in-hospital CA were recorded in patients admitted to a hospital 
with suspected or confirmed NSTE-ACS in the derivation cohort (n=242 303). Patients with 
in-hospital CA were more likely to be older, have electrocardiographic ST-T-abnormalities, 
previous history of heart failure, and diabetes, lower systolic blood pressure, hemoglobin, and 
lower renal function (eGFR), higher heart rate and blood glucose level, and higher Killip class 
(table 1).  
 
Among patients with a final diagnosis of NSTE-ACS (n=102 650), there were 1.3% (n=1365) 
cases of in-hospital CA (supplementary figure 2). For patients with NSTE-ACS, invasive 
coronary treatment (PCI or CABG surgery) during index hospitalization was recorded for 581 
(42.6%) cases with in-hospital CA and 53 063 (52.4%) cases without in-hospital CA. The 
majority of patients who were not diagnosed with ACS (n=139 653) had a final diagnosis of 
stable angina pectoris or non-cardiac chest pain (supplementary figure 3). Among patients 
without ACS there were 0.5% (n=712) cases of in-hospital CA. 
 
Derivation of the risk score 
Five variables independently predicting in-hospital CA were included in the final risk score 
model. We developed a points score with a maximal sum of seven points whereby the 
included variables were: age \HDUVSRLQWelectrocardiographic ST-T abnormalities (2 
points), .LOOLS&ODVV! SRLQWKHDUW UDWHRUESPSRLQWDQGV\VWROLFEORRG 
pressure <100 mmHg (2 points) (table 2). For simplicity, two variables, glucose >10 mmol/L 
and eGFR <30 mL/min per 1.73 m2, were omitted and did not substantially alter the model 
performance. The observed proportions of in-hospital CA by sum of points in the derivation 
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cohort, in total, ranged between 0.17% and 8.53 % (figure 2a and supplementary table 1a). 
The majority of patients had a point score sum between 1 and 3 points (supplementary table 
1b). Discrimination was good (c-statistic 0.72 [95% CI, 0.71-0.73]) and the calibration plot 
showed reasonable agreement, but with a tendency towards overestimation of risk with a 
higher sum of score points (figure 3a). A higher risk score was associated with higher in-
hospital mortality in the complete case cohort, ranging from 0.06% to 28.2% for patients 
without in-hospital CA vs. 20.5% to 50.0% for patients experiencing in-hospital CA. 
Analyses restricted to first-time admissions (n=187 662) showed similar results regarding 
discrimination (c-statistic 0.73 [95% CI, 0.72-0.74]) and calibration (data not shown). 
 
Sensitivity analyses 
For the five variables included in the points score model, there was 5.9% missing data in the 
derivation cohort. Complete case analyses demonstrated similar results regarding model 
performance as for the main analyses (supplementary figure 4). Patients excluded due to 
missing data for in-hospital CA (n=13 281) resembled patients without in-hospital CA in the 
cohort regarding baseline characteristics and had comparable though slightly lower in-hospital 
and 30-day mortality rates. Patients excluded due to missing data for cardiopulmonary 
resuscitation prior to admission (n=54 221) were of similar age, slightly more likely to be 
female and had a lower burden of prior disease compared with patients without in-hospital 
CA in the cohort. Presentation characteristics were not comparable because of missing data 
(about 80%) (supplementary table 2). In-hospital and 30-day mortality was comparable to the 
cohort in total. 
 
Temporal validation 
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A temporal validation from SWEDEHEART 2005-2007 was performed and showed good 
agreement in respect of discrimination (c-statistic 0.74 [95% CI, 0.73-0.76]) and calibration 
(figure 3b). Analyses restricted to first-time admissions (n=102 762) showed similar results 
regarding discrimination (c-statistic 0.75 [95% CI, 0.74-0.77]) and calibration (data not 
shown). 
 
External validation 
There were 6388 (2.3%) cases of in-hospital CA recorded in the MINAP cohort (n=276 109). 
The vast majority of patients in the cohort (87%) had a final diagnosis of NSTE-ACS. The 
cumulative incidence of in-hospital CA was 2.3% in patients with NSTE-ACS and no ACS 
alike. Patients with in-hospital CA in the MINAP cohort compared with the SWEDEHEART 
derivation cohort were older (median 80 years vs. 75 years), but comparable with regards to a 
lower systolic blood pressure, lower hemoglobin level, and lower renal function, higher heart 
rate, and higher blood glucose level compared to those without in-hospital CA 
(supplementary table 3). The yearly incidence of in-hospital CA was higher for both NSTE-
ACS and non-ACS than in SWEDEHEART (supplementary figure 2). Patients with a low 
sum of risk score points had a comparable risk of in-hospital CA regardless of a final 
diagnosis of NSTE-ACS or not. However, for patients with a sum of risk score points in the 
upper range, those without ACS were much higher risk (figure 2c and supplementary table 
1a). 
 
Discrimination was moderate (c-statistic 0.65 [95% CI, 0.65-0.66]) and the calibration plot 
showed a general underestimation of predicted risk (figure 3c). A sensitivity analysis 
including only complete cases regarding Killip class, but with imputed data regarding the 
remaining variables in the risk score model showed similar discrimination (c-statistic 0.67 
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[95% CI, 0.66-0.68] and had a similar calibration plot (supplementary figure 5). When 
adjusting for the underlying risk in the MINAP cohort by replacing ß0, calibration was good 
in the lower range of sum of points, but with an increasing sum of points, a general 
overestimation of risk was observed (supplementary figure 6). Additional data on the MINAP 
cohort with complete cases only regarding Killip class is found in the supplementary material 
(supplementary tables 4-6 and supplementary figure 7). 
 
Discussion 
 Our study confirms that CA is a rare, yet not negligible complication following 
hospitalization for NSTE-ACS, affecting 1.3-2.3% of patients. For patients admitted with 
suspected NSTE-ACS, this study shows that the risk of in-hospital CA may be estimated 
using the SAFER score, consisting of five clinical findings (systolic blood pressure, age, heart 
rate, ECG changes, and heart failure signs) readily available on admission to hospital. 
Discrimination of CA was good in the development and internal validation cohorts, though 
less so in the external validation cohort. 
 
The CCU was introduced in the early 1960s, enabling patients with ACS to have continuous 
ECG monitoring where life-threating arrhythmias could be swiftly detected and treated by 
trained personnel13. With the development and improvement of care and outcomes for 
patients with ACS, questions have been raised about the need and cost effectiveness for low-
risk patients to be admitted to the CCU14. Current guidelines recommend that patients with 
non-ST elevation myocardial infarction and low risk for arrhythmias could be initially 
monitored in a CCU or an intermediate care unit likewise5. van Diepen and colleagues 
reported that in a population based cohort of nearly 8000 patients with stable NSTE-ACS, the 
majority of patients (65%) were admitted to a CCU but had no differences in clinical 
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outcomes compared with those hospitalized in a cardiology telemetry ward (35%)15. The 
SAFER score could help the clinician select higher-risk patients that may benefit from 
monitoring in a CCU and lower-risk patients where monitoring in a cardiology telemetry 
ward may be sufficient. 
  
The usefulness of this point score for excluding patients without need for rhythm monitoring 
is probably limited. In the SWEDEHEART cohort the risk of in-hospital CA rarely fell below 
0.5% and in the MINAP cohort, patients with 1 risk score point had more than 1% risk of in-
hospital CA. However, equipment for heart rhythm monitoring is a scarce resource in many 
low- and middle-income countries16. In a limited resource setting, our point score could help 
decide who should be monitored. However, for any risk score model, it is important to 
consider the population under investigation and the underlying risk; application of the SAFER 
score to a different population would require an evaluation of underlying risk and external 
validation of the score. 
 
We have not been able to evaluate the effect of the duration of cardiac monitoring, as the date 
and time of in-hospital CA was not recorded. However, in a study from Piccini and 
colleagues, patients with NSTE-ACS were as likely to have VT/VF after as before 48 hours 
and 38% had VT/VF after revascularization2. Therefore, a high-risk patient probably would 
benefit from extended monitoring and also here the SAFER score might aid in targeting 
patients. 
 
Our findings are in concordance with a study by Goldman et al from 1996, which evaluated 
patients admitted with chest pain and the risk of in-hospital CA. Similar to our study, they 
found that five factors on admission (ST-segment elevation or Q-waves on initial ECG, ST-
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segment depression or T-wave inversion on initial ECG, systolic blood pressure below 110 
mm Hg, pulmonary rales above the bases, and worsening of known ischemic heart disease) 
were predictive of major in-hospital complications including CA17.  
 
Although our study was based on a nationwide cohort of patients admitted with suspected 
NSTE-ACS, it has limitations. We were unable to differentiate between VT, VF and asystole/ 
pulseless electrical activity resulting in CA. There were missing data for in-hospital CA and 
CA prior to admission and for MINAP, Killip class was missing in a large proportion of 
patients, which could have decreased model discrimination. Data on timing of in-hospital CA 
were not available and the temporal relationship to revascularization could not be assessed. 
Notably, all study patients were admitted to a CCU because of suspected or confirmed NSTE-
ACS and, therefore, patients with a final diagnosis of non-ACS cannot be compared to 
patients with undifferentiated chest patient in the emergency ward. This was particularly clear 
for the MINAP cohort, for whom non-ACS patients had an incidence of in-hospital CA equal 
to patients with NSTE-ACS. 
 
Conclusion 
We have shown that a simple risk score model, developed and validated in large national 
cohorts, including five easily accessible variables, predicts the risk of in-hospital CA for 
patients admitted with suspected NSTE-ACS and may help the clinician to choose proper 
level of surveillance. 
 
Conflicts of interest 
None 
 
 15 
Acknowledgements 
This study has been made possible by support from the Swedish Foundation for Strategic 
Research. KS was supported by the Stockholm County Council (clinical research 
appointment). 
 16 
References 
1. Al-Khatib SM, Granger CB, Huang Y, Lee KL, Califf RM, Simoons ML, 
Armstrong PW, Van de Werf F, White HD, Simes RJ, Moliterno DJ, Topol EJ, Harrington 
RA. Sustained ventricular arrhythmias among patients with acute coronary syndromes with no 
st-segment elevation: Incidence, predictors, and outcomes. Circulation. 2002;106:309-312 
2. Piccini JP, White JA, Mehta RH, Lokhnygina Y, Al-Khatib SM, Tricoci P, 
Pollack CV, Jr., Montalescot G, Van de Werf F, Gibson CM, Giugliano RP, Califf RM, 
Harrington RA, Newby LK. Sustained ventricular tachycardia and ventricular fibrillation 
complicating non-st-segment-elevation acute coronary syndromes. Circulation. 2012;126:41-
49 
3. Pokorney SD, Radder C, Schulte PJ, Al-Khatib SM, Tricocci P, Van de Werf F, 
James SK, Cannon CP, Armstrong PW, White HD, Califf RM, Gibson CM, Giugliano RP, 
Wallentin L, Mahaffey KW, Harrington RA, Newby LK, Piccini JP. High-degree 
atrioventricular block, asystole, and electro-mechanical dissociation complicating non-st-
segment elevation myocardial infarction. American heart journal. 2016;171:25-32 
4. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Jr., Ganiats TG, Holmes 
DR, Jr., Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, 
Peterson ED, Sabatine MS, Smalling RW, Zieman SJ. 2014 aha/acc guideline for the 
management of patients with non-st-elevation acute coronary syndromes: A report of the 
american college of cardiology/american heart association task force on practice guidelines. 
Journal of the American College of Cardiology. 2014;64:e139-228 
5. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, 
Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, 
Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S, Baumgartner H, Gaemperli 
O, Achenbach S, Agewall S, Badimon L, Baigent C, Bueno H, Bugiardini R, Carerj S, 
 17 
Casselman F, Cuisset T, Erol C, Fitzsimons D, Halle M, Hamm C, Hildick-Smith D, Huber 
K, Iliodromitis E, James S, Lewis BS, Lip GY, Piepoli MF, Richter D, Rosemann T, Sechtem 
U, Steg PG, Vrints C, Luis Zamorano J. 2015 esc guidelines for the management of acute 
coronary syndromes in patients presenting without persistent st-segment elevation: Task force 
for the management of acute coronary syndromes in patients presenting without persistent st-
segment elevation of the european society of cardiology (esc). European heart journal. 
2016;37:267-315 
6. Jernberg T, Attebring MF, Hambraeus K, Ivert T, James S, Jeppsson A, 
Lagerqvist B, Lindahl B, Stenestrand U, Wallentin L. The swedish web-system for 
enhancement and development of evidence-based care in heart disease evaluated according to 
recommended therapies (swedeheart). Heart (British Cardiac Society). 2010;96:1617-1621 
7. Avezum A, Piegas LS, Goldberg RJ, Brieger D, Stiles MK, Paolini R, Huang 
W, Gore JM. Magnitude and prognosis associated with ventricular arrhythmias in patients 
hospitalized with acute coronary syndromes (from the grace registry). The American journal 
of cardiology. 2008;102:1577-1582 
8. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, 
Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate 
glomerular filtration rate. Annals of internal medicine. 2009;150:604-612 
9. Sullivan LM, Massaro JM, D'Agostino RB, Sr. Presentation of multivariate data 
for clinical use: The framingham study risk score functions. Statistics in medicine. 
2004;23:1631-1660 
10. Van Houwelingen JC, Le Cessie S. Predictive value of statistical models. 
Statistics in medicine. 1990;9:1303-1325 
11. Herrett E, Smeeth L, Walker L, Weston C. The myocardial ischaemia national 
audit project (minap). Heart (British Cardiac Society). 2010;96:1264-1267 
 18 
12. Cattle BA, Baxter PD, Greenwood DC, Gale CP, West RM. Multiple imputation 
for completion of a national clinical audit dataset. Statistics in medicine. 2011;30:2736-2753 
13. Braunwald E. Evolution of the management of acute myocardial infarction: A 
20th century saga. Lancet. 1998;352:1771-1774 
14. Silverman MG, Morrow DA. Hospital triage of acute myocardial infarction: Is 
admission to the coronary care unit still necessary? American heart journal. 2016;175:172-
174 
15. van Diepen S, Lin M, Bakal JA, McAlister FA, Kaul P, Katz JN, Fordyce CB, 
Southern DA, Graham MM, Wilton SB, Newby LK, Granger CB, Ezekowitz JA. Do stable 
non-st-segment elevation acute coronary syndromes require admission to coronary care units? 
American heart journal. 2016;175:184-192 
16. Bestawros M. Electrophysiology in the developing world: Challenges and 
opportunities. Cardiology clinics. 2017;35:49-58 
17. Goldman L, Cook EF, Johnson PA, Brand DA, Rouan GW, Lee TH. Prediction 
of the need for intensive care in patients who come to the emergency departments with acute 
chest pain. The New England journal of medicine. 1996;334:1498-1504 
  
 19 
FIGURE LEGENDS 
 
Figure 1. Flow chart: Exclusion and inclusion criteria in the SWEDEHEART derivation 
cohort. One patient could have more than one exclusion criterion. STEMI, ST-elevation 
myocardial infarction; NSTE-ACS, non-ST elevation acute coronary syndrome; CA, cardiac 
arrest. 
 
Figure 2a. Estimated risk, observed proportions of in-hospital cardiac arrest (CA) and 
distribution of patients per sum of risk score points in the SWEDEHEART derivation cohort. 
Total (n=242 303). No ACS (n=139 653). NSTE-ACS (n=102 650).  CA, cardiac arrest; 
NSTE-ACS, non-ST elevation acute coronary syndrome. 
 
Figure 2b. Estimated risk, observed proportions of in-hospital cardiac arrest (CA) and 
distribution of patients per sum of risk score points in the SWEDEHEART temporal 
validation cohort. Total (n=126 073). No ACS (n=82 221). NSTE-ACS (n=43 852). 
 
Figure 2c. Estimated risk, observed proportions of in-hospital cardiac arrest (CA) and 
distribution of patients per sum of risk score points in the MINAP validation cohort. Total 
(n=276 109). No ACS (n=36 131). NSTE-ACS (n=239 978). 
 
Figure 3a. Calibration plot and calculation of c-statistic for the SWEDEHEART derivation 
cohort 2008-2014. C-statistic over imputed data = 0.72 (95% CI 0.71-0.73). ).  CA, cardiac 
arrest. 
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Figure 3b. Calibration plot and calculation of c-statistic for the SWEDEHEART temporal 
validation cohort 2005-2007. c-statistic over imputed data = 0.74 (95% CI 0.73-0.76) 
Figure 3c. Calibration plot and calculation of c-statistic for the MINAP validation cohort 
2008-2013. c-statistic over imputed data = 0.65 (95% CI 0.65-0.66) 
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Table 1. Baseline characteristics for the SWEDEHEART derivation cohort 
Characteristic No cardiac arrest  Cardiac arrest Total Missing 
 (n=240 226) (n=2077) (n=242 303) n (%) 
Demographics     
Age, median (iqr), years 70 (60-79) 75 (66-82) 70 (60-79) 0 (0) 
Men, n (%) 144 259 (60.1) 1337 (64.4) 145 596 (60.1) 0 (0) 
Weight, median (iqr), kg 79 (68-90) 79 (68-90) 79 (68-90) 16 322 (6.7) 
Presentation characteristics     
Systolic blood pressure, median (iqr), mmHg 147 (130-165) 130 (110-151) 147 (130-165) 5925 (2.4) 
Diastolic blood pressure, median (iqr), mmHg 81 (71-92) 78 (65-90) 81 (71-92) 10 026 (4.1) 
Heart rate, median (iqr), bpm 76 (65-91) 87 (70-110) 76 (65-91) 3030 (1.3) 
Killip class > I, n (%) 24 389 (10.4) 526 (26.3) 24 915 (10.5) 5556 (2.3) 
ST-T abnormalities, n (%) 125 254 (53.5) 1597 (79.8) 126 851 (53.7) 5985 (2.5) 
eGFR, CKD-EPI, median (iqr), mL/min per 1.73 m2 76.4 (56.8-90.9) 56.6 (37.9-79.0) 76.3 (56.7-90.9) 18 477 (7.6) 
Glucose, median (iqr), mmol/L 6.5 (5.6-8.1) 8.3 (6.5-11.3) 6.5 (5.6-8.2) 47 516 (19.6) 
Hemoglobin, median (iqr), g/L 138 (126-148) 131 (118-144) 137 (126-148) 24 011 (9.9) 
Medical history     
Current smoker, n (%) 36 457 (16.4) 299 (17.2) 36 756 (16.4) 18 333 (7.6) 
Hypertension, n (%) 143 352 (59.7) 1351 (65.0) 144 703 (59.7) 0 (0) 
Diabetes mellitus, n (%) 58 025 (24.2) 682 (32.8) 58 707 (24.2) 0 (0) 
Prior heart failure, n (%) 40 849 (17.0) 561 (27.0) 4141 (2.0) 0 (0) 
Prior myocardial infarction, n (%) 87 414 (36.4) 890 (42.9) 88 304 (36.4) 0 (0) 
Prior PCI, n (%) 60 671 (25.3) 464 (22.3) 61 135 (25.2) 0 (0) 
Prior CABG, n (%) 29 854 (12.4) 362 (17.4) 30 216 (12.5) 0 (0) 
Prior stroke, n (%) 29 977 (12.5) 362 (17.4) 30 339 (12.5) 0 (0) 
Prior peripheral vascular disease, n (%) 15 487 (6.4) 220 (10.6) 15 707 (6.5) 0 (0) 
Prior chronic obstructive pulmonary disease, n (%) 20 144 (8.4) 227 (10.9) 20 371 (8.4) 0 (0) 
Medication at admission     
Aspirin, n (%) 114 357 (47.8) 1019 (49.8) 115 376 (47.8) 975 (0.4) 
Beta-blocker, n (%) 119 014 (49.8) 1137 (55.7) 120 151 (49.8) 1127 (0.5) 
ACE-inhibitor or ARB, n (%) 103 367 (43.2) 980 (48.0) 104 347 (43.2) 1018 (0.4) 
Calcium antagonist, n (%) 47 657 (19.9) 468 (22.9) 48 125 (20.0) 1142 (0.5) 
Statin, n (%) 100 189 (41.9) 863 (42.2) 101 052 (41.9) 1026 (0.4) 
Oral antidiabetic, n (%) 27 912 (11.7) 282 (13.8) 28 194 (11.7) 867 (0.4) 
Insulin, n (%) 25 843 (10.8) 344 (16.8) 26 187 (10.8) 882 (0.4) 
Variables in the risk score     
Systolic blood pressure < 100 mmHg, n (%) 5658 (2.4) 235 (12.0) 5893 (2.5) 5925 (2.4) 
 25 
AJH\HDUVQ 182 943 (76.2) 1851 (89.1) 184 794 (76.3) 0 (0) 
FUHTXHQF\RIKHDUWUDWHRUESPQ 48 420 (20.4) 864 (42.5) 49 284 (20.6) 3030 (1.3) 
Ecg, changes (ST-T abnormalities) n (%) 125 254 (53.5) 1597 (79.8) 126 851 (53.7) 5985 (2.5) 
Rales (Killip >1), n (%) 24 389 (10.4) 526 (26.3) 24 915 (10.5) 5556 (2.3) 
Bpm: beats per minute; Iqr: interquartile range; eGFR: estimated Glomerular Filtration Rate; PCI: Percutaneous Coronary Intervention; 
CABG: Coronary Artery By-Pass Grafting; ACE: Angiotensin Converting Enzyme.  ARB: Angiotensin II Receptor Blocker. 
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Table 2. Variables included in the final risk score model 
 Predictor ßi** Points*** Point total Estimate of 
risk**** 
Intercept (ß0)  -6.32761  0 0.18 
Systolic Systolic BP 
<100 mmHg 
1.29782 2 1 0.33 
Age* $JH 0.61853 1 2 0.61 
Frequency Heart rate <50 
RUEPS 
0.73144 1 3 1.13 
Ecg ST-T 
abnormalities 
0.97011 2 4 2.08 
Rales Killip class >1 0.60985 1 5 3.79 
 
   6 6.81 
    7 11.94 
*defined as constant B; **estimated regression coefficient; ***Points= ßi / B rounded to the 
nearest integer; **** sum of  (ß0 + point total x B) transformed with the logistic function 
